Date: 2021.5.27 Your Name: Qian Zhang Manuscript Title: Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct CAFs in HNSCC Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Jiangsu Province Science & Technology Department (BE2018618) Nanjing Department of Health (YKK18120) Nanjing Medical Science and technique Development Foundation (QRX17174) Nanjing Clinical Research Center for Oral Diseases (no. 2019060009) Jiangsu Postgraduate Research Innovation Program	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting food	Nana	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	, lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	-		
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports funding from the Jiangsu Province Science & Technology Department (BE2018618), Nanjing Department of Health (YKK18120), Nanjing Medical Science and technique Development Foundation (QRX17174), Nanjing Clinical Research Center for Oral Diseases (no. 2019060009), Jiangsu Postgraduate Research Innovation Program.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021.5.27 Your Name: Yuxin Wang Manuscript Title: Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct CAFs in HNSCC Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Jiangsu Province Science & Technology Department (BE2018618) Nanjing Department of Health (YKK18120) Nanjing Medical Science and technique Development Foundation (QRX17174) Nanjing Clinical Research Center for Oral Diseases (no. 2019060009) Jiangsu Postgraduate Research Innovation Program	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting food	Nana	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	, lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	-		
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports funding from the Jiangsu Province Science & Technology Department (BE2018618), Nanjing Department of Health (YKK18120), Nanjing Medical Science and technique Development Foundation (QRX17174), Nanjing Clinical Research Center for Oral Diseases (no. 2019060009), Jiangsu Postgraduate Research Innovation Program.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021.5.27

Your Name: Chengwan Xia

Manuscript Title: Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct CAFs in HNSCC Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Jiangsu Province Science & Technology Department (BE2018618) Nanjing Department of Health (YKK18120) Nanjing Medical Science and technique Development Foundation (QRX17174) Nanjing Clinical Research Center for Oral Diseases (no. 2019060009) Jiangsu Postgraduate Research Innovation Program	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting food	Nana	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	, lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	-		
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports funding from the Jiangsu Province Science & Technology Department (BE2018618), Nanjing Department of Health (YKK18120), Nanjing Medical Science and technique Development Foundation (QRX17174), Nanjing Clinical Research Center for Oral Diseases (no. 2019060009), Jiangsu Postgraduate Research Innovation Program.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021.5.27 Your Name: Liang Ding Manuscript Title: Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct CAFs in HNSCC Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Jiangsu Province Science & Technology Department (BE2018618) Nanjing Department of Health (YKK18120) Nanjing Medical Science and technique Development Foundation (QRX17174) Nanjing Clinical Research Center for Oral Diseases (no. 2019060009) Jiangsu Postgraduate Research Innovation Program	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months

3	Royalties or licenses	None	
4	Consulting food	Nana	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	, lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	-		
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports funding from the Jiangsu Province Science & Technology Department (BE2018618), Nanjing Department of Health (YKK18120), Nanjing Medical Science and technique Development Foundation (QRX17174), Nanjing Clinical Research Center for Oral Diseases (no. 2019060009), Jiangsu Postgraduate Research Innovation Program.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021.5.27 Your Name: Yumei Pu Manuscript Title: Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct CAFs in HNSCC Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Jiangsu Province Science & Technology Department (BE2018618) Nanjing Department of Health (YKK18120) Nanjing Medical Science and technique Development Foundation (QRX17174) Nanjing Clinical Research Center for Oral Diseases (no. 2019060009) Jiangsu Postgraduate Research Innovation Program	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months

3	Royalties or licenses	None	
4	Consulting food	Nana	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	, lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	-		
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports funding from the Jiangsu Province Science & Technology Department (BE2018618), Nanjing Department of Health (YKK18120), Nanjing Medical Science and technique Development Foundation (QRX17174), Nanjing Clinical Research Center for Oral Diseases (no. 2019060009), Jiangsu Postgraduate Research Innovation Program.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021.5.27 Your Name: Xiaobei Hu Manuscript Title: Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct CAFs in HNSCC Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Jiangsu Province Science & Technology Department (BE2018618) Nanjing Department of Health (YKK18120) Nanjing Medical Science and technique Development Foundation (QRX17174) Nanjing Clinical Research Center for Oral Diseases (no. 2019060009) Jiangsu Postgraduate Research Innovation Program	
2	Grants or contracts from any entity (if not indicated	Time frame: past	36 months
	in item #1 above).		

3	Royalties or licenses	None	
4	Consulting fees	Nana	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	, lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	N	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports funding from the Jiangsu Province Science & Technology Department (BE2018618), Nanjing Department of Health (YKK18120), Nanjing Medical Science and technique Development Foundation (QRX17174), Nanjing Clinical Research Center for Oral Diseases (no. 2019060009), Jiangsu Postgraduate Research Innovation Program.

Please place an "X" next to the following statement to indicate your agreement:

Date:	_2021.5.27
Your Name	e:Huiming Cai
Manuscrip	t Title: Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct CAFs in HNSCC
Manuscrip	t number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Jiangsu Province Science & Technology Department (BE2018618) Nanjing Department of Health (YKK18120) Nanjing Medical Science and technique Development Foundation (QRX17174) Nanjing Clinical Research Center for Oral Diseases (no. 2019060009) Jiangsu Postgraduate Research Innovation Program		
	Time frame: past 36 months			

	r		T
2	Grants or contracts from any entity (if not indicated	None	
	in item #1 above).		
3	Royalties or licenses	None	
5	Royalles of licenses		
-	Consulting for a	Nexe	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Nanjing Nuoyuan Medical	
	financial interests	Devices Co., LTD	

Dr. **Cai** reports funding from Jiangsu Province Science & Technology Department (BE2018618), Nanjing Department of Health (YKK18120), Nanjing Medical Science and technique Development Foundation (QRX17174), Nanjing Clinical Research Center for Oral Diseases (no. 2019060009), Jiangsu Postgraduate Research Innovation Program. Dr. **Cai** is from Nanjing Nuoyuan Medical Devices Co., LTD.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021.5.27 Your Name: Qingang Hu Manuscript Title: Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct CAFs in HNSCC Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Jiangsu Province Science & Technology Department (BE2018618) Nanjing Department of Health (YKK18120) Nanjing Medical Science and technique Development Foundation (QRX17174) Nanjing Clinical Research Center for Oral Diseases (no. 2019060009) Jiangsu Postgraduate Research Innovation Program	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
7	Support for attending	None	
'	meetings and/or travel	None	
8	Patents planned, issued or	None	
Ũ	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
10			
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
15	financial interests		

The author reports funding from the Jiangsu Province Science & Technology Department (BE2018618), Nanjing Department of Health (YKK18120), Nanjing Medical Science and technique Development Foundation (QRX17174), Nanjing Clinical Research Center for Oral Diseases (no. 2019060009), Jiangsu Postgraduate Research Innovation Program.

Please place an "X" next to the following statement to indicate your agreement: